InnoCare Pharma Past Earnings Performance
Past criteria checks 0/6
InnoCare Pharma has been growing earnings at an average annual rate of 21.1%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been growing at an average rate of 42.8% per year.
Key information
21.1%
Earnings growth rate
60.4%
EPS growth rate
| Biotechs Industry Growth | 11.0% |
| Revenue growth rate | 42.8% |
| Return on equity | -7.0% |
| Net Margin | -60.3% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How InnoCare Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 781 | -471 | 520 | 817 |
| 31 Mar 24 | 715 | -761 | 560 | 794 |
| 31 Dec 23 | 739 | -631 | 551 | 757 |
| 30 Sep 23 | 721 | -584 | 598 | 723 |
| 30 Jun 23 | 757 | -867 | 625 | 732 |
| 31 Mar 23 | 696 | -781 | 606 | 660 |
| 31 Dec 22 | 625 | -887 | 614 | 649 |
| 30 Sep 22 | 503 | -987 | 562 | 605 |
| 30 Jun 22 | 1,187 | -296 | 516 | 815 |
| 31 Mar 22 | 1,111 | -78 | 475 | 759 |
| 31 Dec 21 | 1,043 | -65 | 437 | 722 |
| 30 Sep 21 | 982 | 60 | 337 | 678 |
| 30 Jun 21 | 102 | -266 | 286 | 356 |
| 31 Mar 21 | 52 | -329 | 222 | 380 |
| 31 Dec 20 | 1 | -391 | 158 | 403 |
| 30 Sep 20 | 1 | -1,853 | 131 | 382 |
| 30 Jun 20 | 1 | -2,155 | 105 | 349 |
| 31 Mar 20 | 1 | -2,148 | 86 | 281 |
| 31 Dec 19 | 1 | -2,141 | 67 | 213 |
| 30 Sep 19 | 2 | -742 | 51 | 190 |
| 30 Jun 19 | 2 | -592 | 29 | 181 |
| 31 Mar 19 | 2 | -571 | 24 | 165 |
| 31 Dec 18 | 2 | -550 | 18 | 150 |
| 31 Dec 17 | 0 | -342 | 15 | 63 |
Quality Earnings: 9969 is currently unprofitable.
Growing Profit Margin: 9969 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 9969 is unprofitable, but has reduced losses over the past 5 years at a rate of 21.1% per year.
Accelerating Growth: Unable to compare 9969's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 9969 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (13.8%).
Return on Equity
High ROE: 9969 has a negative Return on Equity (-6.98%), as it is currently unprofitable.